Leadership

Dr Bart serves as the Chief Executive Officer for Trial Professionals Consultant Group  Inc. In this role he serves as a C-level executive within multiple organizations. He has been actively involved in research dating back to 1984 while working in a laboratory focusing on Neuropharmacology. After obtaining his Bachelor of Science in both Biology and Chemistry at Northeastern Illinois University, as well as a Doctorate in Medicine from Rush University in Chicago. Dr Bart went on to do his postdoctoral training in Pediatric Transplantation, Family Medicine with emphasis in Obstetrics and Gynecology at the University of Pittsburgh, and the University of South Florida. He is both Board certified and a Certified Physician Investigator with a broad therapeutic scope and is an industry key opinion leader in several areas. Dr Bart has successfully completed more than 500 clinical trials as the Principal Investigator and functioned as coordinating Investigator across a spectrum of studies that encompass first in human phase 1 through phase 4 programs. These programs have been both domestic as well as international. Dr Bart has had a successful private practice as well as leadership positions in several organizations. Prior to founding TPC he was the President, and Chief Medical Officer for Optimal Research an industry leading site network, Chief Medical Officer of Accelovance,  a vaccine and Immunology focused CRO. Chief Medical Officer and member of the Board of Directors for Idis, a global leader in named patient programs operating in more than 150 countries worldwide.  Chief Medical Officer and Executive Director of Business Development and Client Services for SNBL Clinical Pharmacology Center, and the Medical Director for Radiant Research over the past 25 years. Dr Bart has held faculty positions at Penn State University, and the University of Maryland Medical Center. He has published many articles in prestigious journals. 

As CEO of Trial Professionals Consultant Group, Dr Bart leads one of the top clinical research consulting firms in the industry and looks forward to making your development program a success.

Dr. Elias Ketiar,  MD MD(Res) MRCP, VP, Head UK/EU Operations 

 Over the last six years Elias has worked as a Senior Medical Director developing new therapeutic strategies and supporting clinical training for PPD. He has proven success and experience in clinical trial design, execution and governance. He is skilled at scientific writing, retrospective and prospective large dataset analysis, medical education, training, mentorship and academic and clinical supervision.

With extensive experience in General Medicine and Cardiometabolic Diseases a Member of Royal College of Physicians MRCP (London), UK. His academic research experience involved pioneering research into genetic causes of congenital heart disease, culminating with a Medical Doctorate, St George’s University of London. 

His extensive leadership and management skills have honed by more than 20 years of clinical service in the NHS UK and private healthcare. He has experience and appreciation of healthcare systems globally and has always been interested and involved in medical education and clinical trials. 

He delivers training regularly on the topic of Cardiometabolic Diseases and holistic General Medicine to clinical and non-clinical teams. Elias’ experience has given him the opportunity to gain formal expertise in multinational trial protocol development and writing; contribution to and review of supporting patient materials – print and apps; leadership in project planning and risk mitigation; medical safety strategy; clinical operations and site management; quality systems and efficiency; operational governance and process development; acting as the clinical therapeutic area lead in reviewing the content of various plans outlining the roles for sponsors and the CRO relative to the conduct of a clinical trial.

Elias applies his practical clinical knowledge and innovates to generate solutions - enhancing patient pathway design resulting in successful trial recruitment, particularly in complicated therapeutic areas.

Kenneth L Duchin, PhD, Chief Science Officer

Ken Duchin is the Chief Science Officer of Trial Professionals Consultant Group. He earned his BA in chemistry at Drew University and received his PhD degree in pharmacology from the College of Medicine and Dentistry of New Jersey. He completed his post-doctoral training in renal physiology at University of Colorado. He joined ER Squibb and Sons and became Executive Director, Human Pharmacology and was responsible for various clinical pharmacology programs in several therapeutic areas and served as Team Leader for Fosinopril He then joined IVAX Corporation and was involved in the development of complex generic products and novel oncology and urological products. After 8 years, he moved to Noven Pharmaceuticals where he led the clinical development of Daytrana (transdermal methylphenidate). He also worked for Theravance in South San Francisco as Head of Clinical Pharmacology. In addition, he managed preclinical and clinical programs at TheraVida, a company with a product for overactive bladder and ProtaMed a company that focused on amyloid diseases. Ken also spent 3 years at Asubio Pharmaceuticals as Executive Director, Clinical Pharmacology and Global Project Leader. Since 2015, he has been an independent consultant assisting companies with their pre-clinical, clinical pharmacology and clinical research needs, medical writing, scientific due diligence. and business development. Ken has held teaching positions at Barry University and Medical College of Pennsylvania and served on the editorial board for the Journal of Clinical Pharmacology. His publications include over 45 peer reviewed articles, several book chapters and co-inventor on 9 patents.

Holly Ford Hoefer, MS, Chief Marketing Officer 

Holly Hoefer is the Chief Marketing Officer of Trial Professionals Consultant Group. Holly’s tenure within the biotech industry began in 2001, serving in various leadership roles within Fortune 500 companies.  Her work has been strategically focused in the areas of health literacy, marketing, health economics and patient recruitment.    Utilizing the latest in patient recruitment techniques, coupled with cutting edge technology and ICD10 data, Holly has successfully planned and recruited patients for over 50 clinical trials in various therapeutic areas and phases, with a primary focus in oncology, infectious disease, bariatrics, and vaccines.  She has authored several whitepapers and contributed to articles covering new and emerging therapies.  

Holly draws from her years of experience in patient-centric engagement, to design and brand trials, while educating patients in innovative ways.  Her focus is always ‘engineered engagement’ to promote randomization into clinical trials that achieve either on time, or early enrollment.  Holly’s work is notable within a high-profile clientele and touts a successful track record designing outreach for recruiting FIH - Ph. 4 studies.   

Holly holds an MS in Heath Communications from Boston University and a CPC-H in hospital billing and coding with a strong background in health economics.  Holly is also GCP certified.

Dawn McCollough, Chief Business Officer

Dawn has overseen clinical trial support functions and clinical trials involving thousands of patients across numerous indications, geographies and stages of development for nearly 25 years. 

Dawn began consultation services in 2018 via her firm and Trial Professionals Consultant Group Inc., in addition to her role at MPBC. She provides consultation to a variety of pharmaceutical, biotech and CRO clients.

Previously, she headed clinical operations functions in start-up Biotech organizations, headed medical research operations, including the medical research team in late-stage development at Biogen. Prior to that, Dawn was head of the global monitoring organization for North America at Novartis Vaccines and Diagnostics, based in Cambridge, MA. She began her career with Novartis as Global Head of Clinical Trial Governance and was based in Siena Italy. 

Throughout the course of her career, she has participated in the development of numerous drug products from concept to approval. In addition to her time spent in US, she has worked extensively in Europe, Canada, Latin America, and Asia. Dawn has been chosen as a top Women’s Leader within previously affiliated organizations. 

Dawn has an entrepreneurial spirit and is passionate about developing new options for patients and for people. Dawn enjoys travel, has a very strong connection with animals, nature and anything outdoors, toes the line at ultra-marathons about which she knows “the only way out is through” but revels in the journey, and enjoys spending time with friends and family.